US3085944A - Free-flowing intrinsic factor concentrate - Google Patents
Free-flowing intrinsic factor concentrate Download PDFInfo
- Publication number
- US3085944A US3085944A US23140A US2314060A US3085944A US 3085944 A US3085944 A US 3085944A US 23140 A US23140 A US 23140A US 2314060 A US2314060 A US 2314060A US 3085944 A US3085944 A US 3085944A
- Authority
- US
- United States
- Prior art keywords
- intrinsic factor
- factor concentrate
- free
- concentrate
- flowing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940070385 intrinsic factor concentrate Drugs 0.000 title claims description 25
- 239000000463 material Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 235000012241 calcium silicate Nutrition 0.000 description 7
- 239000004115 Sodium Silicate Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000378 calcium silicate Substances 0.000 description 6
- 229910052918 calcium silicate Inorganic materials 0.000 description 6
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 6
- 229940029329 intrinsic factor Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 229910052911 sodium silicate Inorganic materials 0.000 description 6
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 6
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 208000031845 Pernicious anaemia Diseases 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229910001514 alkali metal chloride Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910052915 alkaline earth metal silicate Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000005049 silicon tetrachloride Substances 0.000 description 1
- -1 sodium calcium aluminum Chemical compound 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Definitions
- Instrinsic factor is a heat labile component of normal human gastric juice.
- Evidence presently indicates that intrinsic factor is involved in the utilization of vitamin B
- small oral doses of vitamin B are ineffective unless a source of intrinsic factor is administered simultaneously.
- the study of gastric intestinal absorption with radioactive vitamin B in pernicious anemia patients and healthy individuals has proven that intrinsic factor is essential for this absorption.
- hematopoietic responses in pernicious anemia may follow the oral administration of massive doses of vitamin B given without the intrinsic factor, the absorption of the vitamin, when amounts comparable to those found in an average diet are indigestcd, involves a participation of intrinsic factor.
- Intrinsic factor concentrate is usually prepared from animal stomach and/or intestines, particularly hog duodenum or pyloric mucosa.
- the intrinsic factor concentrate produced by the known methods is a lumpy amorphous product usually dried by lyophilizing or spraydrying, which cannot be milled and has a very strong inherent odor.
- the aggregate nature of this concentrate is due to a residual moisture content which cannot be removed without destroying its therapeutic activity. It is also difficult to prepare homogeneous blends of the concentrate because of its heterogeneous lumpy consistency, its lack of mobility, and its adherence to container walls.
- My invention is based upon the discovery that the lumpy foul-smelling intrinsic factor concentrate produced by the known methods is transformed into a dry powder of more agreeable odor by intermixing, in proper proportions, the intrinsic factor concentrate with certain siliceous materials.
- the resulting product is free-flowing and does not tend to adhere to the walls of the container in which it is prepared, and is readily millable to any desired particle size.
- one part of the siliceous material is mixed with from about 16 parts to about 32 parts of intrinsic factor concentrate and dry-blended by barrel-rolling, followed by milling through a comminuting apparatus equipped with a number 80 mesh screen.
- the final product is a cream-colored, free-flowing intrinsic factor concentrate of more agreeable odor.
- Siliceous materials which may be used in accordance "ice with the present invention are finely divided pulverulent materials containing in excess of about to 98 percent siliceous material by weight on the water-free basis and having an average ultimate particle size below 0.1 micron, preferably in the range of 0.01 to 0.05 micron.
- Typical materials of this character are finely divided silica, calcium silicate, magnesium silicate, sodium aluminum silicate, sodium calcium aluminum silicate, aluminum silicate, and the like.
- Siliceous materials particularly suitable for the present invention may be prepared in several ways.
- Pyrogenic silica for example, is prepared by the vapor phase flame pyrolysis of silicon tetrachloride and has an average ultimate particle size of from about 0.01 micron to about 0.03 micron.
- Finely divided silica having a surface area in the range of 25 to 250 square meters per gram and an average ultimate particle size below 0.1 micron may also be prepared by a precipitation method which involves reacting an aqueous solution of an alkali metal silicate such as sodium silicate with an acid. By carefully controlling the concentration of the reactants, the temperature conditions, rate of addition of acid, etc., it is possible to precipitate a product having finely-divided, discrete particles as compared to the gel resulting from processes commonly known in the art.
- This precipitation method consists, more particularly, in adding an acid to an alkali metal silicate having a predetermined concentration.
- the acid is added to the silicate solution since the rate of neutralization of the alkali metal silicate is important. For instance, were the silicate solution to be added to an excess of acid, the former would be neutralized too rapidly and the conventional gel would be produced.
- the alkali metal silicate used in preparing a finely divided silica is sodium silicate, it should normally have the composition 'Na O(SiO Where x is at least 2, usually 2 to 4, including fractional numbers, preferably in the range of 3 to 4.
- the silicate solution generally contains 10 to 100 grams of SiO per liter.
- Precipitated silica having the properties set forth above may be prepared by still another method.
- a finely divided alkaline earth metal silicate such as calcium silicate, having an average ultimate particle size below 0.1 micron
- an acid having an anion which forms a water soluble salt with the alkaline earth metal
- a siliceous material particularly useful for the present invention is prepared.
- Calcium silicates having a surface area in the range of 25 to 250 square meters per gram and an average ultimate particle size below 0.1 micron are best prepared by reacting calcium chloride with an alkali metal silicate in aqueous medium containing sodium chloride or like alkali metal chloride.
- the sodium chloride conveniently may be in the calcium chloride solution although it may also be in the sodium silicate solution. It has been found that the presence of sodium chloride materially improves the character of the siliceous material.
- the amount of calcium chloride is generally in stoichiomet-ric excess of the sodium silicate. Although a slight excess of sodium silicate is tolerable, it is best to have at least a stoichiometric amount of calcium chloride present during the reaction.
- sodium silicate having the composition Na O(SiO where x is a number not less than 2 nor more than 4 is preferably used. This results in the production of a calcium silicate having a composition CaO(SiO where x is as defined above.
- the proportion of intrinsic factor concentrate to siliceous material may be as high as about 98% intrinsic factor concentrate to about 2% siliceous material and as low as about 93% intrinsic factor concentrate to about 7% siliceous material. Above about 7% by weight of siliceous material the final product tends to dust into the atmosphere, whereas below about 2% by weight of siliceous material the final product is still lumpy and amorphous. However, for optimum results, we prefer to employ from about 3% to about 6% by weight of the siliceous material based on the weight of the intrinsic factor concentrate.
- Example 1 Five parts of silicon dioxide having an average ultimate particle size of from 0.01 to 0.10 micron was mixed with 95 parts of intrinsic factor concentrate and dry-blended by barrel-rolling, followed by milling through a comminuting apparatus equipped with a number 80 mesh screen. The final product was a cream-colored, freefiowing powder which was readily incorporated in dry vitamin preparations.
- Example 2 Five parts of calcium silicate having an average ultimate particle size of from 0.01 to 0.10 micron was mixed with 95 parts of intrinsic factor concentrate and dryblended by barrel-rolling, followed by milling through a comminuting apparatus equipped with a number mesh screen. The final product was a cream-colored, freeflowing powder which was readily acceptable for market distribution.
- a stable, substantially dry, free-flowing powder comprising intrinsic fiactor concentrate and a siliceous material, said powder containing not substantially less than 93% intrinsic factor concentrate by weight, and said siliceous material having a surface area of from about 25 to about 250 square meters/ gram and being present in an amount not substantially more than about 7% by weight.
- a process for the production of a stable, substantially dry, free-flowing powder containing a major amount of intrinsic factor concentrate which comprises adding an amount, not substantially less than 93 parts by weight, of intrinsic factor concentrate to not substantially more than 7 parts by weight of a siliceous material having an average ultimate particle size of from about 0.01 micron to about 0.10 micron and a surface area of from about 25 to 250 square meters/ gram and thoroughly'lblending the mixture so obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Description
United States Patent 3,085,944 FREE-FLOWING INTRINSIC FACTOR CONCENTRATE William Valentine, Nanuet, N.Y., assignor to American I(vllyanarnid Company, New York, N.Y., a corporation of arne No Drawing. Filed Apr. 19, 1960, Ser. No. 23,140 3 Claims. (Cl. 167-74) This invention relates to novel therapeutic compositions of matter and, more particularly, to intrinsic factor concentrate prepared as dry powders by intermixing it with certain siliceous materials whereby a substantially dry, free-flowing intrinsic factor concentrate is obtained.
Instrinsic factor is a heat labile component of normal human gastric juice. Evidence presently indicates that intrinsic factor is involved in the utilization of vitamin B In the classical condition in which a deficiency of intrinsic factor is found, namely pernicious anemia, small oral doses of vitamin B are ineffective unless a source of intrinsic factor is administered simultaneously. The study of gastric intestinal absorption with radioactive vitamin B in pernicious anemia patients and healthy individuals has proven that intrinsic factor is essential for this absorption. Although hematopoietic responses in pernicious anemia may follow the oral administration of massive doses of vitamin B given without the intrinsic factor, the absorption of the vitamin, when amounts comparable to those found in an average diet are indigestcd, involves a participation of intrinsic factor.
Intrinsic factor concentrate is usually prepared from animal stomach and/or intestines, particularly hog duodenum or pyloric mucosa. The intrinsic factor concentrate produced by the known methods is a lumpy amorphous product usually dried by lyophilizing or spraydrying, which cannot be milled and has a very strong inherent odor. The aggregate nature of this concentrate is due to a residual moisture content which cannot be removed without destroying its therapeutic activity. It is also difficult to prepare homogeneous blends of the concentrate because of its heterogeneous lumpy consistency, its lack of mobility, and its adherence to container walls.
Usually, patients Who need intrinsic factor concentrate in large doses are seriously ill with pernicious anemia. Such patients are made even more ill upon oral administration of intrinsic factor concentrate by reason of its repulsive consistency and nauseating odor. Furthermore, these undesirable properties make it diificult to incorporate intrinsic factor concentrate into elegant pharmaceutical formulations. Also, because of its lumpy amorphous nature, intrinsic factor concentrate cannot be milled nor reduced in particle size to less than 80 mesh.
My invention is based upon the discovery that the lumpy foul-smelling intrinsic factor concentrate produced by the known methods is transformed into a dry powder of more agreeable odor by intermixing, in proper proportions, the intrinsic factor concentrate with certain siliceous materials. The resulting product is free-flowing and does not tend to adhere to the walls of the container in which it is prepared, and is readily millable to any desired particle size.
In practicing this invention, one part of the siliceous material is mixed with from about 16 parts to about 32 parts of intrinsic factor concentrate and dry-blended by barrel-rolling, followed by milling through a comminuting apparatus equipped with a number 80 mesh screen. The final product is a cream-colored, free-flowing intrinsic factor concentrate of more agreeable odor.
Siliceous materials which may be used in accordance "ice with the present invention are finely divided pulverulent materials containing in excess of about to 98 percent siliceous material by weight on the water-free basis and having an average ultimate particle size below 0.1 micron, preferably in the range of 0.01 to 0.05 micron. Typical materials of this character are finely divided silica, calcium silicate, magnesium silicate, sodium aluminum silicate, sodium calcium aluminum silicate, aluminum silicate, and the like.
Siliceous materials particularly suitable for the present invention may be prepared in several ways. Pyrogenic silica, for example, is prepared by the vapor phase flame pyrolysis of silicon tetrachloride and has an average ultimate particle size of from about 0.01 micron to about 0.03 micron.
Finely divided silica having a surface area in the range of 25 to 250 square meters per gram and an average ultimate particle size below 0.1 micron may also be prepared by a precipitation method which involves reacting an aqueous solution of an alkali metal silicate such as sodium silicate with an acid. By carefully controlling the concentration of the reactants, the temperature conditions, rate of addition of acid, etc., it is possible to precipitate a product having finely-divided, discrete particles as compared to the gel resulting from processes commonly known in the art.
This precipitation method consists, more particularly, in adding an acid to an alkali metal silicate having a predetermined concentration. The acid is added to the silicate solution since the rate of neutralization of the alkali metal silicate is important. For instance, were the silicate solution to be added to an excess of acid, the former would be neutralized too rapidly and the conventional gel would be produced.
The surface areas mentioned herein are measured by the Brunauer-Emmett-Teller (B.E.T.) method which is described in the Journal of the American Chemical Society, volume 60, page 309 (1938).
When the alkali metal silicate used in preparing a finely divided silica is sodium silicate, it should normally have the composition 'Na O(SiO Where x is at least 2, usually 2 to 4, including fractional numbers, preferably in the range of 3 to 4. The silicate solution generally contains 10 to 100 grams of SiO per liter.
Precipitated silica having the properties set forth above may be prepared by still another method. Thus, by reacting a finely divided alkaline earth metal silicate, such as calcium silicate, having an average ultimate particle size below 0.1 micron, with an acid having an anion which forms a water soluble salt with the alkaline earth metal, a siliceous material particularly useful for the present invention is prepared.
Calcium silicates having a surface area in the range of 25 to 250 square meters per gram and an average ultimate particle size below 0.1 micron are best prepared by reacting calcium chloride with an alkali metal silicate in aqueous medium containing sodium chloride or like alkali metal chloride. The sodium chloride conveniently may be in the calcium chloride solution although it may also be in the sodium silicate solution. It has been found that the presence of sodium chloride materially improves the character of the siliceous material.
The amount of calcium chloride is generally in stoichiomet-ric excess of the sodium silicate. Although a slight excess of sodium silicate is tolerable, it is best to have at least a stoichiometric amount of calcium chloride present during the reaction.
To insure production of the calcium silicate in la finely divided state, sodium silicate having the composition Na O(SiO where x is a number not less than 2 nor more than 4, is preferably used. This results in the production of a calcium silicate having a composition CaO(SiO where x is as defined above. When calcium silicate prepared in the fashion just described is treated with a mineral acid, in the manner disclosed above, a dry, powdered silica in extremely fine state of division is produced.
On a weight/weight basis the proportion of intrinsic factor concentrate to siliceous material may be as high as about 98% intrinsic factor concentrate to about 2% siliceous material and as low as about 93% intrinsic factor concentrate to about 7% siliceous material. Above about 7% by weight of siliceous material the final product tends to dust into the atmosphere, whereas below about 2% by weight of siliceous material the final product is still lumpy and amorphous. However, for optimum results, we prefer to employ from about 3% to about 6% by weight of the siliceous material based on the weight of the intrinsic factor concentrate.
The following examples will serve to illustrate my invention:
Example 1 Five parts of silicon dioxide having an average ultimate particle size of from 0.01 to 0.10 micron was mixed with 95 parts of intrinsic factor concentrate and dry-blended by barrel-rolling, followed by milling through a comminuting apparatus equipped with a number 80 mesh screen. The final product was a cream-colored, freefiowing powder which was readily incorporated in dry vitamin preparations.
Example 2 Five parts of calcium silicate having an average ultimate particle size of from 0.01 to 0.10 micron was mixed with 95 parts of intrinsic factor concentrate and dryblended by barrel-rolling, followed by milling through a comminuting apparatus equipped with a number mesh screen. The final product was a cream-colored, freeflowing powder which was readily acceptable for market distribution.
What is claimed is:
1. A stable, substantially dry, free-flowing powder comprising intrinsic fiactor concentrate and a siliceous material, said powder containing not substantially less than 93% intrinsic factor concentrate by weight, and said siliceous material having a surface area of from about 25 to about 250 square meters/ gram and being present in an amount not substantially more than about 7% by weight.
2. A stable, substantially dry, free-flowing powder as in claim 1 wherein the average ultimate particle size of said siliceous material is between about 0.01 micron and about 0.10 micron.
3. A process for the production of a stable, substantially dry, free-flowing powder containing a major amount of intrinsic factor concentrate, which comprises adding an amount, not substantially less than 93 parts by weight, of intrinsic factor concentrate to not substantially more than 7 parts by weight of a siliceous material having an average ultimate particle size of from about 0.01 micron to about 0.10 micron and a surface area of from about 25 to 250 square meters/ gram and thoroughly'lblending the mixture so obtained.
References Cited in the file of this patent UNITED STATES PATENTS 2,059,811 Sauer Nov. 3, 1936 2,830,010 Valentine et al Apr. 8, 1958 2,879,161 Valentine etral Mar. 24, 1959 2,949,400 Sieger et a1 Aug. 16, 1960
Claims (1)
1. A STABLE, SUBSTANTIALLY DRY, FREE-FLOWING POWDER COMPRISING INTRINSIC FACTOR CONCENTRATE AND A SILICEOUS MATERIAL, SAID POWDER CONTAINING NOT SUBSTANTIALLY LESS THAN 93% INTRINSIC FACTOR CONCENTRATE BY WEIGHT, AND SAID SILICEOUS MATERIAL HAVING A SURFACE AREA OF FROM ABOUT 25 TO ABOUT 250 SQUARE METERS/GRAM AND BEING PRESENT IN AN AMOUNT NOT SUBSTANTIALLY MORE THAN ABOUT 7% BY WEIGHT.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23140A US3085944A (en) | 1960-04-19 | 1960-04-19 | Free-flowing intrinsic factor concentrate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23140A US3085944A (en) | 1960-04-19 | 1960-04-19 | Free-flowing intrinsic factor concentrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3085944A true US3085944A (en) | 1963-04-16 |
Family
ID=21813333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US23140A Expired - Lifetime US3085944A (en) | 1960-04-19 | 1960-04-19 | Free-flowing intrinsic factor concentrate |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3085944A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3247064A (en) * | 1962-03-30 | 1966-04-19 | Shionogi & Co | Multivitamin tablet stabilized with porous silica |
| US3267030A (en) * | 1962-05-09 | 1966-08-16 | Solvay | Extinguisher powders based on alkali metal bicarbonates |
| US3290163A (en) * | 1963-10-30 | 1966-12-06 | Chas Elbreder & Company Inc | Free flowing treatment of glass beads |
| US3644215A (en) * | 1968-12-03 | 1972-02-22 | Degussa | Process for converting liquid antioxidants to pulverulent form |
| US4116772A (en) * | 1975-07-30 | 1978-09-26 | Pennwalt Corporation | Free-flowing fungal enzyme composition |
| US4684534A (en) * | 1985-02-19 | 1987-08-04 | Dynagram Corporation Of America | Quick-liquifying, chewable tablet |
| US20110098365A1 (en) * | 2008-05-01 | 2011-04-28 | Stephen John Minter | Salt product |
| US9808030B2 (en) | 2011-02-11 | 2017-11-07 | Grain Processing Corporation | Salt composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2059811A (en) * | 1927-11-11 | 1936-11-03 | Fissan Exp Company Julius Bloc | Composition of matter for use as a vehicle for other substances, and a process of producing the same |
| US2830010A (en) * | 1956-05-14 | 1958-04-08 | American Cyanamid Co | Powder-filled hexylresorcinol capsules |
| US2879161A (en) * | 1956-05-14 | 1959-03-24 | American Cyanamid Co | Stable dry powder compositions containing choline chloride and methods of preparing same |
| US2949400A (en) * | 1956-07-26 | 1960-08-16 | American Cyanamid Co | Stable anti-hemorrhagic powders |
-
1960
- 1960-04-19 US US23140A patent/US3085944A/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2059811A (en) * | 1927-11-11 | 1936-11-03 | Fissan Exp Company Julius Bloc | Composition of matter for use as a vehicle for other substances, and a process of producing the same |
| US2830010A (en) * | 1956-05-14 | 1958-04-08 | American Cyanamid Co | Powder-filled hexylresorcinol capsules |
| US2879161A (en) * | 1956-05-14 | 1959-03-24 | American Cyanamid Co | Stable dry powder compositions containing choline chloride and methods of preparing same |
| US2949400A (en) * | 1956-07-26 | 1960-08-16 | American Cyanamid Co | Stable anti-hemorrhagic powders |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3247064A (en) * | 1962-03-30 | 1966-04-19 | Shionogi & Co | Multivitamin tablet stabilized with porous silica |
| US3267030A (en) * | 1962-05-09 | 1966-08-16 | Solvay | Extinguisher powders based on alkali metal bicarbonates |
| US3290163A (en) * | 1963-10-30 | 1966-12-06 | Chas Elbreder & Company Inc | Free flowing treatment of glass beads |
| US3644215A (en) * | 1968-12-03 | 1972-02-22 | Degussa | Process for converting liquid antioxidants to pulverulent form |
| US4116772A (en) * | 1975-07-30 | 1978-09-26 | Pennwalt Corporation | Free-flowing fungal enzyme composition |
| US4684534A (en) * | 1985-02-19 | 1987-08-04 | Dynagram Corporation Of America | Quick-liquifying, chewable tablet |
| US20110098365A1 (en) * | 2008-05-01 | 2011-04-28 | Stephen John Minter | Salt product |
| US8435555B2 (en) | 2008-05-01 | 2013-05-07 | Eminate Limited | Salt product |
| US9491961B2 (en) | 2008-05-01 | 2016-11-15 | Eminate Limited | Salt product |
| US9808030B2 (en) | 2011-02-11 | 2017-11-07 | Grain Processing Corporation | Salt composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3138525A (en) | Castor wax-amprotropine-resin compositions | |
| EP0011489B1 (en) | An analgesic effervescent powder and process for its preparation | |
| AU2004260652C1 (en) | Calcium carbonate granulation | |
| AU2007303786B2 (en) | Composition comprising crustacean gastrolith components, calcium carbonate and its use | |
| US3337404A (en) | Effervescent potassium composition | |
| JPH0257058B2 (en) | ||
| US3085944A (en) | Free-flowing intrinsic factor concentrate | |
| US3579634A (en) | Novel antacid compositions and methods for their administration | |
| US3160565A (en) | Enhancing the absorption of orally administered medicament with disaccharide fatty acid esters | |
| US4985593A (en) | Magnesium potassium citrate | |
| US4704278A (en) | Fluidized magaldrate suspension | |
| IL32020A (en) | Antacid compositions | |
| JPH02180814A (en) | Granulated composition and method thereof | |
| US4895980A (en) | Method of manufacturing magnesium potassium citrate | |
| JP2891744B2 (en) | Calcium pantothenate composition and method for producing the same | |
| US3202578A (en) | Polymeric laxative composition and method of using same | |
| US2970889A (en) | Process for the manufacture of magnesium aluminosilicate for medical uses | |
| EP1274447A1 (en) | Pharmaceutical composition with a content of calcium or mixture of calcium and vitamin d or mixture of calcium and magnesium in a new formulation | |
| DE2402413A1 (en) | STABILIZED POWDER | |
| US4399128A (en) | Pharmaceutical carrier and compositions | |
| US3131121A (en) | Highly acidic cation exchange resin containing amprotropine cations | |
| US4839173A (en) | Modified clays, preparation thereof and therapeutical compositions containing the same | |
| CA1252045A (en) | Fluidized magaldrate suspension | |
| US4889725A (en) | Means to promote the neutralization reaction between particulate calcium carbonate and ionized phosphate | |
| JPS61118321A (en) | Fluidizable and rehydratable magaldlate composition |